 BELLUS Health Inc NASDAQ: BLU has announced a positive interim analysis from Phase 2b SOOTHE trial of BLU-5937 for refractory chronic cough RCC. BLU-5937, the Companys lead program, is a highly selective P2X3 antagonist. 